Bayer: Macular Edema trials

The registry lists 16 Macular Edema studies with Bayer as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 3 7Phase 4 3No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular DegenerationCompletedNCT06591598Phase 4Results posted
• A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)CompletedNCT05850520Phase 3Results posted
• A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular EdemaCompletedNCT05511038Phase 4Results posted
• Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)CompletedNCT02818998Phase 3Results posted
• Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.CompletedNCT02581995Phase 4Results posted
• Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central InvolvementCompletedNCT01783886Phase 3Results posted
• Intravitreal Aflibercept Injection in Vision Impairment Due to DMECompletedNCT01331681Phase 3Results posted
• Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)CompletedNCT01012973Phase 3Results posted
• A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular EdemaActive, not recruitingNCT06929143
• A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular EdemaCompletedNCT06422507Phase 3
• A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their DiseaseCompletedNCT03161912
• A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular OedemaCompletedNCT02850263
• Special Drug Use Investigation of EYLEA for Diabetic Macular EdemaCompletedNCT02425501
• Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)CompletedNCT02040220
• Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF TherapyCompletedNCT01771081
• Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)CompletedNCT01512966Phase 3